Cork firm gets a taste of the Orient

A number of Chinese companies are visiting Cork this week at the invitation of Ringaskiddy-headquartered Zenith Technologies.

The aim of the visit is to enable Zenith to showcase its products in the fields of automation, process control and manufacturing execution systems. The Chinese firms come from the pharmaceutical, life sciences and biotechnology sectors.

Chief executive a of Zenith Technologies, Brendan O’Regan, said it was important that these companies see at firsthand how solutions developed by Irish engineers and technologists are embedded in the operations of some of the leading multinational companies.

“It is important too that they understand the business reasons why some of the leading global brands in pharma, biopharmaceutical, ICT and healthcare base themselves in Ireland and how comprehensive Irish design, engineering and technology services are in improving efficiency and operations,” he said.

The Chinese market is experiencing rapid growth in demand for pharmaceutical products internally combined with a desire by local companies to internationalise, he added.

“This mirrors our experience in Ireland some years ago and increases our value proposition to the Chinese market from an experience and knowledge perspective,” said Mr O’Regan.

The visit is the first of several planned for 2013.

The Chinese State Food and Drug Administration (SFDA) takes many of its policies from the EU model. Mr O’Regan argues that this provides Irish companies with many lucrative opportunities to help Chinese companies meet regulatory and compliance standards.

Agriculture Minister Simon Coveney said. “It is very positive to see a leading Irish business using innovative technologies to generate new business and partnerships in the Chinese market.”

More in this section

Lunchtime News Wrap

A lunchtime summary of content highlights on the Irish Examiner website. Delivered at 1pm each day.

Sign up

Our Covid-free newsletter brings together some of the best bits from, as chosen by our editor, direct to your inbox every Monday.

Sign up